|
||
|
Hi {{ personalization_token('contact.firstname', 'Contract Pharma Reader') }}, Nobody wants to open a Complete Response Letter and see their assay data called out. Yet cell-based assays keep showing up as a recurring theme in FDA CRLs — and I want to unpack why. Join me Tuesday, September 22 at 10:00 AM EDT for: 📋 Cell-Based Assays Under FDA Scrutiny: Lessons from Recent CRLs We'll be walking through a set of recent CRLs to pinpoint exactly where cell-based assays are falling short — then pairing those findings with current FDA guidance to get at what reviewers are actually expecting. The goal is to leave you with concrete steps: how to tighten up assay development, shore up your validation approach, and close the gaps that tend to trigger regulatory pushback. This one's built for teams working on biologics, cell therapies, or gene therapies — anywhere assay performance carries real regulatory weight. Can't make the live session? A recording will be waiting for you afterward.
|
